Nexsen Advances FDA Pathway and Global Expansion for Rapid Point-of-Care Diagnostics

Nexsen Limited ( (AU:NXN) ) just unveiled an update.

Nexsen reported a solid quarter to 31 December 2025, highlighting continued progress across clinical, regulatory and platform development activities, underpinned by $6.9 million in cash reserves earmarked to fund valuation studies, regulatory submissions, kidney diagnostic development and manufacturing scale-up through to commercialisation. The company advanced clinical validation of its GBS rapid sensor at Northern Health in preparation for an FDA 510(k) submission, engaged a specialist regulatory advisory firm, and achieved key development milestones in its kidney diagnostics program aimed at an 850 million patient market, while also strengthening its global clinical reach through the appointment of Professor Shekhar Kumta to the board and establishing a Hong Kong subsidiary as a manufacturing base for Southeast Asia; post quarter-end, Nexsen lodged an FDA 510(k) pre-submission for the GBS sensor and entered discussions on strategic partnerships, positioning the company to accelerate regulatory approval, market entry and adoption of its rapid point-of-care diagnostics in major maternal and kidney disease markets.

More about Nexsen Limited

Nexsen Limited (ASX:NXN) is a medical diagnostics company focused on rapid point-of-care testing, developing a multi-diagnostic platform that delivers results in 15 to 30 minutes for serious conditions that currently rely on centralised laboratory testing. Its key programs target the global maternal health market with a Group B Streptococcus (GBS) rapid sensor and an extensive kidney diagnostic suite for Chronic Kidney Disease and Acute Kidney Injury, addressing large, underserved patient populations across major healthcare systems worldwide.

Average Trading Volume: 283,658

For detailed information about NXN stock, go to TipRanks’ Stock Analysis page.